TADG-12 is a new member of the serine protease family. This novel Tumor Antigen Derived Gene, i.e. TADG, was identified by differential PCR display using both normal ovarian tissue and ovarian carcinoma. More specifically, TADG-12 was identified using primers to the conserved histidine (sense) and the conserved aspartic acid (antisense). Northern blot analysis utilizing cDNA probe from the 5' domain of TADG-12 revealed three transcripts of 2.6kb, 1.7kb, and 0.9kb. The presence of these transcript varients are noted to be overexpressed in several subtypes of ovarian carcinomas, and not in normal ovary.

Reference: Biochimica et Biophysica Acta 1502, (2000) 337 - 350

98-24

Patent Status: Issued US Patents #6,291,663; #6,294,663, #6,942,978; #7,265,216, #7,067,630 + National Filings

License Status: Exclusive Licensing Available in all Fields except Diagnostic

Additional Licensing Partner to further the commercialization of the Vaccine, Small Molecule, Antisense and Gene Therapy applications of this patented technology